IBDEI0PO ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12294,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12294,1,3,0)
 ;;=3^599.0
 ;;^UTILITY(U,$J,358.3,12294,1,4,0)
 ;;=4^Urinary Tract Infection
 ;;^UTILITY(U,$J,358.3,12294,2)
 ;;=^124436
 ;;^UTILITY(U,$J,358.3,12295,0)
 ;;=593.9^^62^737^7
 ;;^UTILITY(U,$J,358.3,12295,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12295,1,3,0)
 ;;=3^593.9
 ;;^UTILITY(U,$J,358.3,12295,1,4,0)
 ;;=4^Renal Insufficiency
 ;;^UTILITY(U,$J,358.3,12295,2)
 ;;=^123849
 ;;^UTILITY(U,$J,358.3,12296,0)
 ;;=625.6^^62^737^1
 ;;^UTILITY(U,$J,358.3,12296,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12296,1,3,0)
 ;;=3^625.6
 ;;^UTILITY(U,$J,358.3,12296,1,4,0)
 ;;=4^Female Stress Incontinence
 ;;^UTILITY(U,$J,358.3,12296,2)
 ;;=^114717
 ;;^UTILITY(U,$J,358.3,12297,0)
 ;;=788.31^^62^737^8
 ;;^UTILITY(U,$J,358.3,12297,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12297,1,3,0)
 ;;=3^788.31
 ;;^UTILITY(U,$J,358.3,12297,1,4,0)
 ;;=4^Urge Incontinence
 ;;^UTILITY(U,$J,358.3,12297,2)
 ;;=^260046
 ;;^UTILITY(U,$J,358.3,12298,0)
 ;;=788.33^^62^737^6
 ;;^UTILITY(U,$J,358.3,12298,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12298,1,3,0)
 ;;=3^788.33
 ;;^UTILITY(U,$J,358.3,12298,1,4,0)
 ;;=4^Mixed Incontinence (M)(F)
 ;;^UTILITY(U,$J,358.3,12298,2)
 ;;=^293936
 ;;^UTILITY(U,$J,358.3,12299,0)
 ;;=599.70^^62^737^2
 ;;^UTILITY(U,$J,358.3,12299,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12299,1,3,0)
 ;;=3^599.70
 ;;^UTILITY(U,$J,358.3,12299,1,4,0)
 ;;=4^Hematuria NOS
 ;;^UTILITY(U,$J,358.3,12299,2)
 ;;=^336751
 ;;^UTILITY(U,$J,358.3,12300,0)
 ;;=599.71^^62^737^3
 ;;^UTILITY(U,$J,358.3,12300,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12300,1,3,0)
 ;;=3^599.71
 ;;^UTILITY(U,$J,358.3,12300,1,4,0)
 ;;=4^Hematuria, Gross
 ;;^UTILITY(U,$J,358.3,12300,2)
 ;;=^336611
 ;;^UTILITY(U,$J,358.3,12301,0)
 ;;=599.72^^62^737^4
 ;;^UTILITY(U,$J,358.3,12301,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12301,1,3,0)
 ;;=3^599.72
 ;;^UTILITY(U,$J,358.3,12301,1,4,0)
 ;;=4^Hematuria, Microscopic
 ;;^UTILITY(U,$J,358.3,12301,2)
 ;;=^336612
 ;;^UTILITY(U,$J,358.3,12302,0)
 ;;=795.00^^62^738^4
 ;;^UTILITY(U,$J,358.3,12302,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12302,1,3,0)
 ;;=3^795.00
 ;;^UTILITY(U,$J,358.3,12302,1,4,0)
 ;;=4^Abnormal Pap
 ;;^UTILITY(U,$J,358.3,12302,2)
 ;;=^328609
 ;;^UTILITY(U,$J,358.3,12303,0)
 ;;=626.8^^62^738^30
 ;;^UTILITY(U,$J,358.3,12303,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12303,1,3,0)
 ;;=3^626.8
 ;;^UTILITY(U,$J,358.3,12303,1,4,0)
 ;;=4^Dysfunctional Bleeding
 ;;^UTILITY(U,$J,358.3,12303,2)
 ;;=^87521
 ;;^UTILITY(U,$J,358.3,12304,0)
 ;;=628.9^^62^738^44
 ;;^UTILITY(U,$J,358.3,12304,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12304,1,3,0)
 ;;=3^628.9
 ;;^UTILITY(U,$J,358.3,12304,1,4,0)
 ;;=4^Female Infertility Nos
 ;;^UTILITY(U,$J,358.3,12304,2)
 ;;=^62820
 ;;^UTILITY(U,$J,358.3,12305,0)
 ;;=610.1^^62^738^45
 ;;^UTILITY(U,$J,358.3,12305,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12305,1,3,0)
 ;;=3^610.1
 ;;^UTILITY(U,$J,358.3,12305,1,4,0)
 ;;=4^Fibrocystic Breast
 ;;^UTILITY(U,$J,358.3,12305,2)
 ;;=^46167
 ;;^UTILITY(U,$J,358.3,12306,0)
 ;;=V10.3^^62^738^49
 ;;^UTILITY(U,$J,358.3,12306,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12306,1,3,0)
 ;;=3^V10.3
 ;;^UTILITY(U,$J,358.3,12306,1,4,0)
 ;;=4^Hx Of Breast Cancer
 ;;^UTILITY(U,$J,358.3,12306,2)
 ;;=^295217
 ;;^UTILITY(U,$J,358.3,12307,0)
 ;;=V10.43^^62^738^50
 ;;^UTILITY(U,$J,358.3,12307,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12307,1,3,0)
 ;;=3^V10.43
 ;;^UTILITY(U,$J,358.3,12307,1,4,0)
 ;;=4^Hx Of Ovarian Cancer
 ;;^UTILITY(U,$J,358.3,12307,2)
 ;;=^295221
 ;;
 ;;$END ROU IBDEI0PO
